Jupiter Asset Management Ltd. Purchases 971,040 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Key Points

• Jupiter Asset Management Ltd. has significantly increased its stake in BioCryst Pharmaceuticals, owning approximately 1.03% of the company after acquiring 971,040 shares in the first quarter, raising their total to over 2.14 million shares.
• Analysts have issued varied price targets for BioCryst Pharmaceuticals, with Needham & Company setting a target at $17.00 and HC Wainwright at $30.00, while the average consensus price target stands at $16.70.
• Currently, institutional investors hold 85.88% of BioCryst Pharmaceuticals' stock, indicating strong backing by hedge funds and investment firms.

Jupiter Asset Management Ltd. boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 82.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,148,969 shares of the biotechnology company's stock after buying an additional 971,040 shares during the period. Jupiter Asset Management Ltd. owned approximately 1.03% of BioCryst Pharmaceuticals worth $16,117,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. XTX Topco Ltd grew its stake in shares of BioCryst Pharmaceuticals by 314.8% during the 1st quarter. XTX Topco Ltd now owns 87,389 shares of the biotechnology company's stock worth $655,000 after acquiring an additional 66,320 shares in the last quarter. GSA Capital Partners LLP grew its position in BioCryst Pharmaceuticals by 69.3% in the first quarter. GSA Capital Partners LLP now owns 278,552 shares of the biotechnology company's stock valued at $2,089,000 after purchasing an additional 114,068 shares in the last quarter. Federated Hermes Inc. increased its stake in BioCryst Pharmaceuticals by 10.1% in the 1st quarter. Federated Hermes Inc. now owns 184,904 shares of the biotechnology company's stock valued at $1,387,000 after buying an additional 16,947 shares during the last quarter. Mackenzie Financial Corp increased its stake in BioCryst Pharmaceuticals by 37.3% in the 1st quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company's stock valued at $872,000 after buying an additional 31,596 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in BioCryst Pharmaceuticals during the 1st quarter worth about $125,000. Institutional investors own 85.88% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BCRX shares. Needham & Company LLC restated a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday. Barclays boosted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Wedbush increased their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st. Finally, JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded up $0.20 during midday trading on Wednesday, reaching $8.56. 1,005,385 shares of the company were exchanged, compared to its average volume of 3,903,666. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -47.30, a price-to-earnings-growth ratio of 1.43 and a beta of 1.10. The business has a 50-day moving average price of $9.46 and a two-hundred day moving average price of $8.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. The business's quarterly revenue was up 49.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.06) EPS. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.